Company: BIAF
Filing Date: 2025-10-27
Form Type: PRER14A
Source: 0001493152-25-019752
Chunk: 6

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-27
Form: PRER14A
Chunk 6
---
 Series B Preferred Stock thereof up to an aggregate of 131,884 shares of our Common          
 Stock, resulting from the triggering of such anti-dilution provision (the “Series B Anti-Dilution Adjustment Proposal”).                  |
| Proposal                                                                                                                                  
 4: To consider and approve an amendment to the 2024 Equity Incentive Plan (the “2024 Plan”) to increase                                   
 the number of shares of Common Stock reserved for issuance thereunder to 750,000 shares from 66,666 shares (the “Plan                     
 Amendment Proposal  ”).                                                                                                                   |
| Proposal 5: To seek authorization to issue securities                                                                                     
 in one or more non-public offerings in accordance with Nasdaq Marketplace Rule 5635(d) (the “Offering Proposal”);                         |
| Proposal 6: To approve any change in control                                                                                              
 under Nasdaq Marketplace Rule 5635(d) that may result from the potential issuance of securities in the non-public offerings               
 (the “Change of Control Proposal”);                                                                                                       |
| Proposal                                                                                                                                  
 No. 7:  To consider and approve the adjournment of the Special Meeting to a later date, if necessary or appropriate, to                   
 permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with,      
 the approval of Warrant Exercise Proposal, the Warrant Anti-Dilution Adjustment Proposal, the Series B Anti-Dilution Adjustment Proposal, 
 the Plan Amendment Proposal, the Offering Proposal and/or the Change of Control Proposal (the “Adjournment Proposal”).                    |

Additionally, the proxies, at their discretion and if designated as such, are authorized to vote upon such other business as may properly come before the Special Meeting or any continuation, postponement, or adjournment thereof.

| 2 |

Who is entitled to vote?

Stockholders as of the close of business on the record date of October [ ], 2025 (the “ Record Date”), are entitled to vote at the Special Meeting or any postponement or adjournment thereof. As of the Record Date, there were 3,633,815 shares of Common Stock outstanding.

How many votes per share of Common Stock held are stockholders entitled to?

Stockholders have one vote per share on all matters presented at the Special Meeting.

What is the difference between holding shares of Common Stock as a “stockholder of record” and holding shares in “street name”?

Shares held as a “stockholder of record” (also called a “registered